PHOENIX CLINICAL TRIALS

Breast Cancer Cervical Cancer COMETI CTC HR+ mBreast Cancer Adj Chemo vs Chemorad for Cervical Ca Characterization of Circulating Tumor Cells from Subjects with A Phase III Trial of Adjuvant Chemotherapy Following Metastatic Breast Cancer Using the CTC-Endocrine Therapy Chemoradiation as Primary Treatment for Locally Advanced Index Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial AI+ Stomatitis Prophylaxis Evaluation of Miracle Mouthwash (MMW) Plus ynecologic Cancer Hydrocortisone and Prednisolone Mouth Rinse as Prophylaxis for Everolimus-Associated Stomatitis Trabectedin +/- PLD Adv Ovarian 2/3 ln A Randomized, Open-Label Study Comparing the Combination B47 Chemo+\-Trastuz HER2low Adj Breast of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® A Randomized Phase III Trial of Adjuvant Therapy Monotherapy for the Treatment of Advanced-Relapsed Comparing Chemotherapy Alone (Six Cycles of Docetaxel Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Leukemia Chemotherapy Plus in Women with Node- CML Observational Trial - SIMPLICITY Positive or High-Risk Node-Negative HER2-Low Invasive Studying Interventions for Managing Patients with Chronic Breast Cancer Myeloid Leukemia in Chronic Phase: The 5-Year Prospective Niriparib vs PhyChice HER2-gBRCA Breast Cohort Study (SIMPLICITY) A Phase III, Randomized, Open Label, Multicenter, Controlled Azacitidine+BSC vs BSC AML Remission Trial of Niraparib Versus Physician’s Choice in Previously- A Phase III, Randomized, Double-Blind, Placebo-Controlled Treated, Her2 Negative, Germline BRCA Mutation-Positive Study to Compare Efficacy and Safety of Oral Azacitidine Breast Cancer Patients Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myloid LY2835219(CDK4/6inh) 3rdln HR+HER2- MBC Leukemia in Complete Remission A Phase II Study of LY2835219 for Patients with Previously Treated Hormone Receptor Positive, HER2 Negative R/R HCL Metastatic Breast Cancer A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Rd Ph2 Lucitanib FGF Aberrant MBC A Phase II, Randomized, Open-Label, Multicenter, Safety and Idela + Ritux, 1Ln CLL, 17p Del Efficacy Study of Oral Lucitanib in Patients with FGF Aberrant A Phase II, Single Arm Study Evaluating the Efficacy and Metastatic Breast Cancer Safety of Idelalisib in Combination with in Patients with Previously Untreated Chronic Lymphocytic Leukemia MM302+Trast vs TPC HER2+ MBC with 17p Deletion A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician’s Choice Lung Cancer Plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer for Sqm or Non-Sqm NSCLC A Phase IIIb/IV Safety Trial of Nivolumab in Subjects with Trast+- TDM1pretreatHer2+MBC Advanced or Metastatic Non-Small Cell Lung Cancer Who A Phase II - Her2-Overexpressing Metastatic Breast Cancer, Have Progressed During or After Receiving At Least One Prior Physicians Choice Plus Trastuzumab Plus Pertuzimab vs Systemic Regimen Physicians Choice Plus Trastuzumab BMS Non-Interventional Stg4 NSCLC & SCLC Lung Cancer Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

For more information or to refer a patient, call 888-972-CURE.

Trial listing current as of 1/2015.. Lung Cancer Continued Pancreatic Cancer LDK378 v SOC ALK+ NSCLC post Chemo/Criz Ph3 Jak Inhibitor w Cape for mPC A Phase III, Multicenter, Randomized, Open-Label Study of A Randomized, Double-Blind, Phase 3 Study of the JAK Oral LDK378 Versus Standard Chemotherapy in Adult Patients 1/2 Inhibitor, or Placebo in Combination with with ALK-Rearranged (ALK-Positive) Advanced Non-Small Capecitabine in Subjects with Advanced or Metastatic Cell Lung Cancer Who Have Been Treated Previously with Adenocarcinoma of the Pancreas Who Have Failed or are Chemotherapy (Platinum Doublet) and Intolerant to First-Line Chemotherapy Lymphomas Renal Cancer CD30 Screening in Solid Tumors and NHL PRINCIPAL Obs Study of in RCC Screening Protocol to Detect Tumor Expression PRINCIPAL: A Prospective Observational Study of Real World Required for Enrollment on Clinical Research Protocols of Treatment Patterns and Treatment Outcomes in Patients with Antibody-Directed Therapy Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib Myeloma Solid Tumors/Hematologic -Rd vs Rd in R/R MM (POLLUX) Signature Series: CDK4/6 Activated Tumor Phase III Study Comparing Daratumumab, , and Modular Phase II Study to Link to Patients with (DRd) vs Lenalidomide and Dexamethasone Pathway Activated Tumors: Module 8 - LEE011 for Patients with (Rd) in Subjects with Relapsed or Refractory Multiple CDK4/6 Pathway Activated Tumors Myeloma Signature Series: BGJ398 FGFR Alteration Nausea/Vomiting Modular Phase II Study to Link Targeted Therapy to Patients with APF530+Placebo v Zofran+placebo CINV HEC Pathway Activated Tumors: Module 6 – BGJ398 for Patients with A Prospective, Randomized, Placebo-Controlled, Double-Blind, Tumors with FGFR Genetic Alterations Multicenter, Phase III Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Signature Series: LDK378 ALK ROS1 Aberrations Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention Modular Phase II Study to Link Targeted Therapy to Patients with of Chemotherapy-Induced Nausea and Vomiting in Subjects Pathway Activated Tumors: Module - 7 (LDK378) For Receiving Highly Emetogenic Chemotherapy Patients Whose Tumors Have Aberrations in ALK or ROS1 Ovarian Cancer Ph2 DNIB0600A vs Doxorubicin Plat Resist Ovarian A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer

The US Oncology Network is supported by McKesson Specialty Health. © 2015 McKesson Specialty Health. All rights reserved.